Génome Canada

Génome Canada

October 26, 2006 10:00 ET

Media Advisory: First Annual Genome Canada International Conference

2020 Vision: Variation and Function in the Genome

OTTAWA, ONTARIO--(CCNMatthews - Oct. 26, 2006) - Journalists are invited to Genome Canada's first international conference, which is designed to anticipate the future of genomic and proteomic science and its impact on society over the next decade and beyond. Participants will discuss emerging genomic tools and discoveries, with integrated consideration of scientific and ethical, economic, legal and other societal issues.

WHEN: October 25 to 27, 2006

WHERE: Chateau Frontenac, Quebec City

There will be sessions on human disease, molecular evolution and biosphere diversity, and emerging technologies and their possible implications. Please join us for a look into the future.


October 27, 2006 - 1:00 pm - Salle de Bal

Allen Roses

Senior Vice President, Pharmacogenetics, GlaxoSmithKline

Dr. Roses was appointed Senior VP for Genetics Research at GlaxoSmithKline in 2000. He was one of the first clinical neurologists to apply molecular genetic strategies to neurological diseases. His laboratory at Duke University reported the chromosomal location for more than 15 diseases, including several muscular dystrophies and Lou Gehrig's disease. He led the team that identified APOE as a major, widely-confirmed susceptibility gene in common late-onset Alzheimer's disease. Translation of these finding to pathway analyses, drug discovery and development has continued at GSK.

A full program, including speaker biographies is available online at http://www.genomecanada.ca/conference/.

Media registration is free but you must register on site.

Contact Information

  • To set up an interview with Allen Roses:
    Genome Canada
    Marc Desmarais, V-P Government Relations
    613-751-4460 ext 115, cell: 613-794-3142
    Genome Canada
    Claudine Renauld, V-P Communications and Public Affairs
    613-751-4460 ext 129